TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15485403

Group type: EXPERIMENTAL
Intervention: Losartan-based antihypertensive therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo-based conventional antihypertensive therapy
Number of subjects: 0
Study: 11487451

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (conjugated estrogen with progestin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9271771

Group type: EXPERIMENTAL
Intervention: Real acupressure
Number of subjects: 31
Study: 8204123

Group type: EXPERIMENTAL
Intervention: Accelerated tissue plasminogen activator (t-PA) and intravenous heparin
Number of subjects: 41021

Group type: COMPARATOR
Intervention: Streptokinase and subcutaneous heparin
Number of subjects: 41021

Group type: COMPARATOR
Intervention: Streptokinase and intravenous heparin
Number of subjects: 41021

Group type: COMPARATOR
Intervention: Combination of streptokinase plus t-PA with intravenous heparin
Number of subjects: 41021

Group type: EXPERIMENTAL
Intervention: Accelerated t-PA
Number of subjects: 41021

Group type: EXPERIMENTAL
Intervention: Combination strategy
Number of subjects: 41021
Study: 3732715

Group type: EXPERIMENTAL
Intervention: Diltiazem (360 mg daily)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg daily)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 29669938

Group type: EXPERIMENTAL
Intervention: Canagliflozin (300 mg/d)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 26177984

Group type: EXPERIMENTAL
Intervention: Simulation and PRS voting
Number of subjects: 35

Group type: COMPARATOR
Intervention: Case-based discussion (Control)
Number of subjects: 35
Study: 24172724

Group type: EXPERIMENTAL
Intervention: Olympic weightlifting (OWL)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Plyometric training
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Traditional resistance training (RT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 63
Study: 23011661

Group type: EXPERIMENTAL
Intervention: Hemin plus trypsin
Number of subjects: 28

Group type: COMPARATOR
Intervention: Hemin
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Hemoglobin plus trypsin
Number of subjects: 28

Group type: COMPARATOR
Intervention: Hemoglobin
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Hb plus mucin plus trypsin
Number of subjects: 28

Group type: COMPARATOR
Intervention: Hemin plus mucin
Number of subjects: 28

Group type: COMPARATOR
Intervention: Hb plus mucin
Number of subjects: 28
Study: 20964256

Group type: EXPERIMENTAL
Intervention: Real acupuncture (RA)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Streitberger needle (SN)
Number of subjects: 147
Study: 19065553

Group type: EXPERIMENTAL
Intervention: 1319 nm diode laser (Sciton, Palo Alto, CA)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 940 nm diode laser (Dornier, Kennasaw, GA)
Number of subjects: 24
Study: 16002074

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: CETP-H5
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: MDR1-h10
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: CETP-H13 and MDR1-h4
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: CETP-H5 and MDR1-h10
Number of subjects: 76
Study: 12675716

Group type: EXPERIMENTAL
Intervention: Whole blood
Number of subjects: 33

Group type: COMPARATOR
Intervention: RBCs and FFP
Number of subjects: 33
Study: 10774784

Group type: EXPERIMENTAL
Intervention: Statins (pravastatin or simvastatin)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Dietary treatment alone (matched controls with high cholesterol)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Dietary treatment alone (matched controls with normal cholesterol)
Number of subjects: 41
Study: 8863775

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma method (PRP-PCs)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Buffy coat method (BC-PCs)
Number of subjects: 64
Study: 1736002

Group type: EXPERIMENTAL
Intervention: Perfusion flow rate at 1.75 L.min‐1.m‐2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perfusion flow rate at 2.25 L.min‐1.m‐2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpha-stat method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: pH-stat method
Number of subjects: 0
Study: 6669631

Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zopiclone 3.75 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zopiclone 11.25 mg
Number of subjects: 0
Study: 30730957

Group type: EXPERIMENTAL
Intervention: TXA treatment
Number of subjects: 628

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 628
Study: 30282686

Group type: EXPERIMENTAL
Intervention: Acupuncture at high-sensitised points
Number of subjects: 666

Group type: COMPARATOR
Intervention: Acupuncture at low/non-sensitised points
Number of subjects: 666

Group type: COMPARATOR
Intervention: Waiting-list group (standard acupuncture treatment after the study)
Number of subjects: 666
Study: 27100101

Group type: EXPERIMENTAL
Intervention: Vitamin K2 supplementation (90 μg) and cholecalciferol (10 μg)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Cholecalciferol (10 μg) alone
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Vitamin K2 supplementation
Number of subjects: 38
Study: 25285539

Group type: EXPERIMENTAL
Intervention: Atazanavir, 300 mg/d, with ritonavir, 100 mg/d
Number of subjects: 1809

Group type: EXPERIMENTAL
Intervention: Raltegravir, 400 mg twice daily
Number of subjects: 1809

Group type: EXPERIMENTAL
Intervention: Darunavir, 800 mg/d, with ritonavir, 100 mg/d
Number of subjects: 1809

Group type: EXPERIMENTAL
Intervention: Combined outcomes of all regimens
Number of subjects: 1809

Group type: COMPARATOR
Intervention: Ritonavir-boosted darunavir
Number of subjects: 1809

Group type: COMPARATOR
Intervention: Raltegravir
Number of subjects: 1809
Study: 22918156

Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice daily for 24 weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 20484942

Group type: EXPERIMENTAL
Intervention: High-protein meals with predominantly meat
Number of subjects: 12

Group type: COMPARATOR
Intervention: High-protein meals with predominantly dairy
Number of subjects: 12

Group type: COMPARATOR
Intervention: High-protein meals with predominantly soy
Number of subjects: 12
Study: 17388711

Group type: EXPERIMENTAL
Intervention: Galantamine (8-24 mg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 16143381

Group type: EXPERIMENTAL
Intervention: In-office bleaching with 37% carbamide peroxide + at-home bleaching with 10% carbamide peroxide (G1)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: In-office bleaching with 37% carbamide peroxide + at-home placebo (G2)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: In-office placebo + at-home bleaching with 10% carbamide peroxide (G3)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: In-office placebo + at-home placebo (G4)
Number of subjects: 44
Study: 12378396

Group type: EXPERIMENTAL
Intervention: Lunar stents (12 and 16 mm long, iridium-oxide coated)
Number of subjects: 87
Study: 10475387

Group type: EXPERIMENTAL
Intervention: Patients classified as asymptomatic with mild CNS symptoms
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: Patients classified as asymptomatic with minimal symptoms
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: Patients classified as asymptomatic with more than minimal symptoms
Number of subjects: 685

Group type: COMPARATOR
Intervention: Patients without any symptoms
Number of subjects: 685

Group type: EXPERIMENTAL
Intervention: Patients with mild symptoms
Number of subjects: 685
Study: 7549379

Group type: EXPERIMENTAL
Intervention: Astragalus membranaceus (AM) oral liquor combined with routine therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine therapy alone
Number of subjects: 0
Study: 2149726

Group type: EXPERIMENTAL
Intervention: White light (photon density of 2.3 X 10(15) photons/s/cm2)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Red light
Number of subjects: 18

Group type: COMPARATOR
Intervention: Blue light
Number of subjects: 18
Study: 7023494

Group type: EXPERIMENTAL
Intervention: Fluproquazone (100 mg)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Paracetamol (500 mg)
Number of subjects: 123
Study: 30853317

Group type: EXPERIMENTAL
Intervention: AcrySof IQ PanOptix
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: AT LISA tri 839MP
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: FineVision
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Tecnis ZLB00
Number of subjects: 160

Group type: COMPARATOR
Intervention: Bifocal IOL
Number of subjects: 160
Study: 30096657

Group type: EXPERIMENTAL
Intervention: High-difficulty C‐FiTT with withdrawal content
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: High-difficulty C‐FiTT
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Low-difficulty C‐FiTT
Number of subjects: 550

Group type: COMPARATOR
Intervention: Neutral control group
Number of subjects: 550
Study: 26995369

Group type: EXPERIMENTAL
Intervention: High-sensitive cardiac troponin T (hs-cTnT) levels
Number of subjects: 1133

Group type: EXPERIMENTAL
Intervention: hs-cTnT levels <3 ng/L
Number of subjects: 1133

Group type: EXPERIMENTAL
Intervention: hs-cTnT levels 3-14 ng/L
Number of subjects: 1133

Group type: EXPERIMENTAL
Intervention: hs-cTnT levels ≥14 ng/L
Number of subjects: 1133

Group type: EXPERIMENTAL
Intervention: Crude model of hs-cTnT
Number of subjects: 1133
Study: 24033567

Group type: EXPERIMENTAL
Intervention: Walnut supplement diet (75 g per day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 19
Study: 22061077

Group type: EXPERIMENTAL
Intervention: Prucalopride (2-4 mg daily)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 19189878

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 186

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 186
Study: 17452896

Group type: EXPERIMENTAL
Intervention: Exercise training (12-week program) in RTx patients
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Exercise training (12-week program) in HD patients
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Exercise training (12-week program) in healthy controls
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 72
Study: 15548969

Group type: EXPERIMENTAL
Intervention: Cyclosporine withdrawal after 3 months of treatment with sirolimus
Number of subjects: 64

Group type: COMPARATOR
Intervention: Cyclosporine continued after 3 months of treatment with sirolimus
Number of subjects: 64
Study: 11578152

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (conjugated equine estrogens 0.625 mg plus medroxyprogesterone acetate 2.5 mg daily)
Number of subjects: 2253

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2253
Study: 9758084

Group type: EXPERIMENTAL
Intervention: Oscillometric blood pressure measuring device (Visomat OZ D2 International)
Number of subjects: 407

Group type: COMPARATOR
Intervention: Standard sphygmomanometer
Number of subjects: 407
Study: 7886177

Group type: EXPERIMENTAL
Intervention: Controlled-choice randomized-response technique
Number of subjects: 352

Group type: COMPARATOR
Intervention: Direct-inquiry techniques
Number of subjects: 352
Study: 2954078

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (no prednisolone)
Number of subjects: 45
Study: 29729555

Group type: EXPERIMENTAL
Intervention: Comprehensive Behavioral Intervention for Tics (CBIT)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Psychoeducation and Supportive Therapy (PST)
Number of subjects: 122
Study: 27172286

Group type: EXPERIMENTAL
Intervention: Wedge-shaped resection of the cranial portion of the posterior bony arch during ODLP (group A)
Number of subjects: 75

Group type: COMPARATOR
Intervention: ODLP alone (group B)
Number of subjects: 75
Study: 25303337

Group type: EXPERIMENTAL
Intervention: Liberal paracetamol use
Number of subjects: 120

Group type: COMPARATOR
Intervention: Restricted paracetamol use
Number of subjects: 120
Study: 23635737

Group type: EXPERIMENTAL
Intervention: Retropubic midurethral sling
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Transobturator midurethral sling
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Overall treatment success
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Reduction in Urogenital Distress Inventory scores
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Reduction in Incontinence Impact Questionnaire scores
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: Fewer complications
Number of subjects: 597
Study: 21623248

Group type: EXPERIMENTAL
Intervention: Tubular diskectomy
Number of subjects: 325

Group type: COMPARATOR
Intervention: Conventional microdiskectomy
Number of subjects: 325
Study: 18078862

Group type: EXPERIMENTAL
Intervention: Gemfibrozil treatment
Number of subjects: 1495

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1495
Study: 12624674

Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine (0.5 M)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Gadobutrol (1.0 M)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Gadopentetate dimeglumine (0.5 M)
Number of subjects: 5
Study: 10438389

Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin, twice daily for 5 days
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 7551950

Group type: EXPERIMENTAL
Intervention: Cisplatin given daily with radiotherapy
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Combined modality arms (cisplatin with carboplatin)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy arms
Number of subjects: 170

Group type: COMPARATOR
Intervention: Cisplatin, carboplatin, 5‐fluorouracil, mitomycin‐C
Number of subjects: 170
Study: 2350528

Group type: EXPERIMENTAL
Intervention: Nicardipine 30 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Propranolol 80 mg alone
Number of subjects: 12
Study: 385261

Group type: EXPERIMENTAL
Intervention: Sodium oxyferriscorbone
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (distilled water)
Number of subjects: 46
Study: 31762342

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) based pain education
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study: 30649903

Group type: EXPERIMENTAL
Intervention: Primary ACLR
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: First ACLR
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: Revision ACLR
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: Second primary ACLR
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: Patients with previous ACLR
Number of subjects: 675
Study: 28957940

Group type: EXPERIMENTAL
Intervention: Systemic fibrinolysis (tenecteplase, TNK)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 24293225

Group type: EXPERIMENTAL
Intervention: R&R2MHP cognitive skills program (group treatment)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 38
Study: 24092567

Group type: EXPERIMENTAL
Intervention: Budesonide (200 μg) + Formoterol (6 μg) on demand
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Regular Budesonide (400 μg) on demand
Number of subjects: 66

Group type: COMPARATOR
Intervention: Terbutaline (0.5 mg) on demand
Number of subjects: 66
Study: 22532824

Group type: EXPERIMENTAL
Intervention: Vaccination period (first 7 months of follow-up)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Post-vaccination period (after the vaccination period)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Enrolled at sites providing contraception on-site
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Entered the trial as injectable contraceptive users
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Consistent condom users
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Single partner whose status was HIV-negative
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Two partners both of HIV-unknown status
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Two or more risk factors (marijuana use, heavy drinking, or use of either during sex)
Number of subjects: 352
Study: 19930556

Group type: EXPERIMENTAL
Intervention: Unilateral decompressive craniectomy (DC)
Number of subjects: 74
Study: 17538167

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 431
Study: 15389234

Group type: EXPERIMENTAL
Intervention: Complete revascularization of vessels > or =50% stenoses
Number of subjects: 219

Group type: COMPARATOR
Intervention: Culprit vessel revascularization
Number of subjects: 219
Study: 11788109

Group type: EXPERIMENTAL
Intervention: Transvaginal natural progesterone gel (4% or 8%) applied every other day for six doses per month
Number of subjects: 49
Study: 9516567

Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 88

Group type: COMPARATOR
Intervention: Cyclosporine A (CSA)
Number of subjects: 88
Study: 8035269

Group type: EXPERIMENTAL
Intervention: Early repair (within 6 hours)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Delayed repair (at 96+ hours)
Number of subjects: 32
Study: 3276451

Group type: EXPERIMENTAL
Intervention: Intravenous ranitidine
Number of subjects: 26
Study: 31150517

Group type: COMPARATOR
Intervention: 1-back task
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 2-back task
Number of subjects: 28
Study: 28696573

Group type: EXPERIMENTAL
Intervention: Presence of Q waves on the presenting ECG
Number of subjects: 2723

Group type: COMPARATOR
Intervention: Absence of Q waves on the presenting ECG
Number of subjects: 2723
Study: 26188275

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Dietary habits intervention
Number of subjects: 180
Study: 24113391

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Color duplex ultrasound (CDU)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Computed tomography angiography (CTA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Color duplex ultrasound (CDU) and Contrast-enhanced ultrasound (CEUS)
Number of subjects: 60
Study: 20951752

Group type: EXPERIMENTAL
Intervention: DIET with miracle fruit
Number of subjects: 13

Group type: COMPARATOR
Intervention: REG
Number of subjects: 13
Study: 19181970

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg infusion)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (saline solution)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (zoledronic acid and control)
Number of subjects: 50
Study: 17539921

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15486961

Group type: EXPERIMENTAL
Intervention: 25 g glucose
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 50 g glucose
Number of subjects: 25

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study: 11600554

Group type: EXPERIMENTAL
Intervention: L-thyroxine (mean dose, 85.5 +/‐ 4.3 microg/d)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 10175988

Group type: EXPERIMENTAL
Intervention: Prolonged prophylaxis with enoxaparin (low-molecular-weight heparin) administered during hospitalization and for 3 weeks after discharge
Number of subjects: 100000

Group type: COMPARATOR
Intervention: Short term prophylaxis administered only during hospitalization
Number of subjects: 100000

Group type: EXPERIMENTAL
Intervention: Prolonged LMWH prophylaxis with enoxaparin
Number of subjects: 100000
Study: 8047703

Group type: EXPERIMENTAL
Intervention: Blocked with 18 trials of retroactive inhibition (BL-18)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blocked with 36 trials of retroactive inhibition (BL-36)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blocked without retroactive inhibition (BL-without)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Random subjects
Number of subjects: 0
Study: 3180390

Group type: EXPERIMENTAL
Intervention: Rate‐adaptive temperature‐controlled pacing with Nova MR
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Rate‐adaptive activity‐controlled pacing with Activitrax
Number of subjects: 7

Group type: COMPARATOR
Intervention: VVI or AAI pacing at 70 beats/min (SSI 70)
Number of subjects: 7
Study: 31752604

Group type: EXPERIMENTAL
Intervention: Strategy-based Training to Enhance Memory (STEM) - 8-session treatment protocol incorporating self-generation, spaced learning, and retrieval practice.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo control group (not specified in detail).
Number of subjects: 20
Study: 29668397

Group type: EXPERIMENTAL
Intervention: LED treatment at 2.4 J/cm2 (wavelengths 625, 660, 850 nm) three times a week for 8 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group treated with light that simulated LED
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: LED treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 28347337

Group type: EXPERIMENTAL
Intervention: Physical activity intervention (structured moderate-intensity physical activity program)
Number of subjects: 1635

Group type: COMPARATOR
Intervention: Health education program (control group)
Number of subjects: 1635

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 1635
Study: 25081363

Group type: EXPERIMENTAL
Intervention: 200 ml foam (22 kcal) consumed immediately after main meals (M)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: 200 ml foam (22 kcal) consumed after snacks (S)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: 200 ml foam (22 kcal) consumed in-between snacks and main meals (I)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group (no foam)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Foam consumption at all timings (M, S, I)
Number of subjects: 134
Study: 24034853

Group type: EXPERIMENTAL
Intervention: Smoke Free Homes educational programme
Number of subjects: 700

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 700